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Caveolin-1 is a negative regulator of tumor
growth in glioblastoma and modulates
chemosensitivity to temozolomide
Kevin Quann,1 Donna M. Gonzales,1 Isabelle Mercier,1,2 Chenguang Wang,1 Federica Sotgia,1,2,3 Richard G. Pestell,4
Michael P. Lisanti1,2,3,* and Jean-Francois Jasmin1,2,*
1
Department of Stem Cell Biology & Regenerative Medicine; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; 2The Jefferson Stem Cell Biology
and Regenerative Medicine Center; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; 3Manchester Breast Centre & Breakthrough Breast Cancer
Research Unit; Paterson Institute for Cancer Research; Institute of Cancer Sciences; Manchester Academic Health Science Centre; University of Manchester; Manchester, UK;
4
Department of Cancer Biology; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA
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temozolomide
Abbreviations: Cav-1, Caveolin-1; GBM, glioblastoma multiforme; MAPK, mitogen activated protein kinase; PI3K,
phosphatidylinositol 3-kinase; RPS6, ribosomal protein S6; mTOR, mammalian target of rapamycin; TMZ, temozolomide;
TGFβ, transforming growth factor beta; TGFβRI, transforming growth factor beta receptor I; TP53, tumor protein 53; PTEN,
phosphatase and tensin homolog; p-gp, permeability glycoprotein

Caveolin-1 (Cav-1) is a critical regulator of tumor progression in a variety of cancers where it has been shown to act as either
a tumor suppressor or tumor promoter. In glioblastoma multiforme, it has been previously demonstrated to function as
a putative tumor suppressor. Our studies here, using the human glioblastoma-derived cell line U-87MG, further support
the role of Cav-1 as a negative regulator of tumor growth. Using a lentiviral transduction approach, we were able to stably
overexpress Cav-1 in U-87MG cells. Gene expression microarray analyses demonstrated significant enrichment in gene
signatures corresponding to downregulation of MAPK, PI3K/AKT and mTOR signaling, as well as activation of apoptotic
pathways in Cav-1-overexpressing U-87MG cells. These same gene signatures were later confirmed at the protein level in
vitro. To explore the ability of Cav-1 to regulate tumor growth in vivo, we further show that Cav-1-overexpressing U-87MG
cells display reduced tumorigenicity in an ectopic xenograft mouse model, with marked hypoactivation of MAPK and
PI3K/mTOR pathways. Finally, we demonstrate that Cav-1 overexpression confers sensitivity to the most commonly used
chemotherapy for glioblastoma, temozolomide. In conclusion, Cav-1 negatively regulates key cell growth and survival
pathways and may be an effective biomarker for predicting response to chemotherapy in glioblastoma.

Glioblastoma multiforme (GBM) is the most common and most
deadly primary brain tumor affecting adults. Despite advancements made in surgical, radiological and chemo-therapies for
this grade IV astrocytoma, prognoses have remained very poor:
median survival time from diagnosis remains at 9–15 mo, with
less than 10% of patients surviving beyond 5 y.1,2
Caveolin-1 (Cav-1) is the principle structural protein responsible for the formation of caveolae, or invaginating microdomains,
in the cell membrane. The capacity for Cav-1 to associate with a
wide variety of proteins has implicated it in a number of processes,
ranging from vesicular transport and cholesterol homeostasis to
nitric oxide production and cell migration, among others.3-7 Its
ability to regulate cell cycle progression and intracellular signal
transduction have resulted in the substantial characterization of
Cav-1 in many cancers, where it has been shown to act as both a
tumor suppressor and tumor promoter depending on the tissue

type.8-11 In gliomas, expression of Cav-1 appears to increase proportionally to tumor grade, with most GBM lesions exhibiting
more intense Cav-1 immunoreactivity than their grade II and
III counterparts.12-14 However, little is currently known as to the
role of Cav-1 as it relates to GBM in vivo. Recent in vitro studies
conducted using the GBM-derived cell line U-87MG have demonstrated that Cav-1 acts as a putative tumor suppressor in GBM
by downregulating α5β1 integrin expression and subsequent
TGFβ/SMAD pathway activity.15,16 Consistent with these findings, we here show that U-87MG cells stably overexpressing Cav-1
exhibit diminished mitogenic signaling, upregulated activation of
apoptotic pathways and a significantly decreased ability to form
tumors in vivo. Additionally, we show that expression of Cav-1
confers sensitivity to the alkylating agent temozolomide (TMZ),
the most commonly used chemotherapy for GBM. These studies
further support the role of Cav-1 as a putative tumor suppressor in
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Figure 1. Stable expression of Cav-1 in U-87MG cells. (A) Expression
levels of Cav-1 measured by immunoblot analyses of U-87MG cells
transduced with either LV105 control or LV105 Cav-1 lentivirus. (B) Immunofluorescent staining of Cav-1 in transduced U-87MG cells
(magnification = 40×).

gliomas and serve to underscore the potential of Cav-1 to serve as
a favorable prognostic factor in GBM.
Results
Stable expression of Cav-1 in U-87MG cells. In order to establish durable expression of Cav-1 over time in a cell line model, we
chose to use a lentiviral transduction approach over the transient
transfection methods used in previous in vitro studies.15,16 After
selection with puromycin, U-87MG cells transduced with lentiviral constructs stably expressing full length Cav-1 cDNA (LV105
Cav-1) were shown to effectively upregulate Cav-1 compared with
an empty control lentivirus (LV105 Control) as demonstrated by
western immunoblot (Fig. 1A). Changes in Cav-1 protein expression were also confirmed by immunofluorescence, where overexpressing cells demonstrated increased cytoplasmic and membrane
localization of Cav-1 following lentiviral transduction (Fig. 1B).
Cav-1 regulates cancer-associated gene expression. Using a
microarray consisting of > 20,000 transcript probes, we were able
to identify 2,001 genes (~10%) significantly modulated by Cav-1
overexpression (Tables 1 and 2; Tables S1–3). Gene set enrichment analyses performed on microarray expression data obtained
from LV105 control and LV105 Cav-1 U-87MG cells indicates
that Cav-1 expression corresponds to changes in a variety of cancer-associated gene signatures. Specifically, by comparing expression data to biological process gene ontology sets, it was found
that Cav-1-overexpressing U-87MG cells demonstrated significant (p < 0.001) enrichment among gene sets related to negative
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regulation of signal transduction, MAP-kinase activity, cell
proliferation and transcription (Table 2; Table S1). Signatures
related to caspase activation, apoptosis and the transforming
growth factor β pathway were also highly enriched (Table 2;
Table S1). When expression data was compared with a curated
canonical pathway database, gene sets related to PI3K/AKT,
mTOR and ERK signaling, as well as cell death and extracellular matrix signaling, were found to be significantly enriched
(Table 2; Table S1).
Cav-1 mediates major proliferative and cell-survival pathways. To validate the results obtained from our microarray
analyses, we next sought to confirm Cav-1 mediated modulation of intracellular signaling pathways at the protein level.
Overexpression of Cav-1 in U-87MG cells results in abrogated
activity of proliferative pathways as shown by reduced phosphorylation of ERK1/2 and decreased expression of the cell cycle driver
cyclin D1 when compared with control as shown by western
immunoblot (Fig. 2A). Overexpression of Cav-1 further reduced
the activity of protein synthesis pathways as shown by reduced
activation of the AKT/mTOR/ribosomal protein S6 (RPS6) signaling pathways (Fig. 2B). Additionally, U-87MG cells overexpressing Cav-1 demonstrated increased presence of the apoptosis
activator cleaved caspase 3 (Fig. 2C).
U-87MG cells stably overexpressing Cav-1 exhibit decreased
tumor growth in vivo. To evaluate the ability of Cav-1 to regulate tumorigenicity in vivo, U-87MG cells infected with either
Cav-1-expressing or control lentivirus were injected subcutaneously into the flanks of athymic nu/nu male mice. After 4 wk,
mice were sacrificed and tumors were collected, weighed and
measured. Importantly, mice harboring Cav-1 overexpressing tumors demonstrated markedly reduced (~7-fold) tumor
weights and volumes as compared with their control counterparts
(p < 0.001, Fig. 3A and B).
Cav-1 overexpressing tumors show reduced signaling activity in vivo. Similar to results obtained in vitro, our immunohistochemical analyses show that explanted xenograft tumors
overexpressing Cav-1 demonstrate fewer cells staining positive
for phospho-ERK1/2 and cyclin D1 (Fig. 4). Additionally, RPS6
and MTOR pathways were shown to be silenced in LV105 Cav-1
tumors, as shown by the absence of their active, phosphorylated
isoforms (Fig. 4).
Cav-1 confers chemosensitivity in U-87MG cells. To further examine the effect of Cav-1 on chemotherapeutic-induced
apoptosis, U-87MG cells were stained for the cell death marker
Annexin V and measured by flow cytometry. Cav-1-overexpressing
U-87MG cells cultured for 72 h in the presence of 500 μM of
temozolomide (TMZ), the most commonly used chemotherapeutic for GBM, showed significant reductions in cell viability when
compared with TMZ-treated LV105 control cells (5.5%, p < 0.01,
Fig. 5A). This effect was found to be most pronounced among
cells initiating apoptosis, as Cav-1-overexpressing U-87MG
cells treated with TMZ demonstrated > 400% increase in early
apoptotic cells compared with TMZ-treated LV105 control cells
(p < 0.01, Fig. 5B). Interestingly, although not statistically significant, overexpression of Cav-1 yielded expanded late-apoptotic
and dead cells after 72 h of TMZ treatment (Fig. 5C and D).

Cell Cycle

1511

Table 1. Differential gene expression of Cav-1 overexpressing U-87MG cells
Probe

Fold change

p-value

Description

CCDC3

94.19

0.00E+00

coiled-coil domain containing 3

COL3A1

75.99

0.00E+00

collagen, type III, α 1

MTUS1

46.14

2.77E−10

microtubule associated tumor suppressor 1

NUP210

34.18

5.08E−24

nucleoporin 210 kDa

COL4A1

30.33

1.38E−22

collagen, type IV, α 1

APOE

24.59

0.00E+00

apolipoprotein E

LRRC17

21.54

0.00E+00

leucine rich repeat containing 17

PRL

16.66

1.07E−22

prolactin

SULF1

16.35

5.88E−20

sulfatase 1

UBE2QL1

15.93

0.00E+00

ubiquitin-conjugating enzyme E2Q family-like 1

FAT3

14.40

0.00E+00

FAT tumor suppressor homolog 3 (Drosophila)

CSAG1

13.78

0.00E+00

chondrosarcoma associated gene 1

SOX4

12.86

1.89E−26

SRY (sex determining region Y)-box 4

CTNNA2

12.75

0.00E+00

catenin (cadherin-associated protein), α 2

GPM6B

11.94

1.51E−14

glycoprotein M6B

CSAG1|CSAG2|CSAG3

11.88

1.42E−15

chondrosarcoma associated gene 1|CSAG family, member 2|CSAG family, member 3

COL1A2

11.26

0.00E+00

collagen, type I, α 2

RCAN2

11.10

7.01E−45

regulator of calcineurin 2

MAF

10.52

2.69E−11

v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian)

CGNL1

10.41

5.06E−26

cingulin-like 1

ARHGAP28

10.03

4.15E−29

Rho GTPase activating protein 28

MGAT4A

9.69

7.01E−45

mannosyl (α-1,3-)-glycoprotein β-1,4-N-acetylglucosaminyltransferase, isozyme A

WISP2

9.27

4.48E−44

WNT1 inducible signaling pathway protein 2

SULF2

9.21

4.22E−15

sulfatase 2

CBLN2

8.73

1.58E−39

cerebellin 2 precursor

CELF2

8.36

0.00E+00

CUGBP, Elav-like family member 2

QPRT

8.31

3.44E−39

quinolinate phosphoribosyltransferase

CALCA

7.63

3.89E−12

calcitonin-related polypeptide α

ALX4

7.62

8.08E−32

ALX homeobox 4

EPHA3

7.53

0.00E+00

EPH receptor A3

CD33

7.53

1.37E−40

CD33 molecule

TNFRSF9

7.12

0.00E+00

tumor necrosis factor receptor superfamily, member 9

KIT

6.96

7.30E−37

v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog

FOXO1

6.82

1.16E−14

forkhead box O1

F2RL2

6.59

4.88E−33

coagulation factor II (thrombin) receptor-like 2

ZNF229

6.58

0.000241

zinc finger protein 229

CCDC69

6.55

2.06E−28

coiled-coil domain containing 69

MEX3A

6.51

3.28E−21

mex-3 homolog A (C. elegans)

CKB

6.47

4.76E−42

creatine kinase, brain

THY1

6.30

8.38E−18

Thy-1 cell surface antigen

ABLIM1

6.12

1.62E−30

actin binding LIM protein 1

PCDH7

6.04

1.54E−29

protocadherin 7

SLC9A3R1

6.02

0.00E+00

solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1

BIRC7

5.98

2.51E−17

baculoviral IAP repeat-containing 7

MEF2C

5.86

6.40E−43

myocyte enhancer factor 2C

Top 100 microarray hits demonstrating the most significantly up- and downregulated genes in Cav-1 overexpressing U-87MG cells. For a complete list
see Table S2. (n = 3 samples from each group).
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Table 1. Differential gene expression of Cav-1 overexpressing U-87MG cells (continued)
Probe

Fold change

p-value

Description

PIK3R3

5.80

2.36E−18

phosphoinositide-3-kinase, regulatory subunit 3 (gamma)

CD24

5.61

4.33E−22

CD24 molecule

CALCB

5.58

0.00E+00

calcitonin-related polypeptide β

UGT2B4

5.56

9.90E−13

UDP glucuronosyltransferase 2 family, polypeptide B4

SGCD

5.55

7.22E−35

sarcoglycan, delta (35 kDa dystrophin-associated glycoprotein)

DLX4

5.50

0.00E+00

distal-less homeobox 4

TP53

5.49

1.54E−28

tumor protein p53

BCL2L11

5.33

1.26E−27

BCL2-like 11 (apoptosis facilitator)

MDK

5.33

2.69E−32

midkine (neurite growth-promoting factor 2)

COL14A1

5.30

1.96E−19

collagen, type XIV, α 1

DPP4

5.25

8.24E−31

dipeptidyl-peptidase 4

FRMPD4

5.12

1.69E−10

FERM and PDZ domain containing 4

SORL1

5.06

5.16E−10

sortilin-related receptor, L(DLR class) A repeats-containing

RCOR2

5.02

1.79E−18

REST corepressor 2

LCP1

−4.95

1.89E−14

lymphocyte cytosolic protein 1 (L-plastin)

EPHB2

−4.99

3.43E−18

EPH receptor B2

LOC100509788…

−5.04

1.15E−14

hypothetical LOC100509788|hypothetical LOC100507248

ID1

−5.06

4.56E−35

inhibitor of DNA binding 1, dominant negative helix-loop-helix protein

IL13RA2

−5.25

0.00E+00

interleukin 13 receptor, α 2

NAV2

−5.25

0.00E+00

neuron navigator 2

TOX2

−5.28

1.60E−37

TOX high mobility group box family member 2

HLA-DRB1…

−5.30

9.97E−19

major histocompatibility complex, class II, DR β 1…

FST

−5.32

5.01E−29

follistatin

KRT15

−5.33

3.11E−35

keratin 15

CRYM

−5.40

6.12E−17

crystallin, mu

AFF3

−5.52

7.41E−14

AF4/FMR2 family, member 3

NAMPT

−5.54

0.00E+00

nicotinamide phosphoribosyltransferase

COL4A6

−5.56

1.74E−21

collagen, type IV, α 6

HS3ST2

−5.63

8.54E−29

heparan sulfate (glucosamine) 3-O-sulfotransferase 2

DNER

−5.92

9.79E−12

delta/notch-like EGF repeat containing

C3orf14

−5.94

4.38E−22

chromosome 3 open reading frame 14

TXNIP

−6.02

5.66E−32

thioredoxin interacting protein

IL8

−6.44

1.49E−36

interleukin 8

GALNT12

−6.73

4.86E−30

UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 12
(GalNAc-T12)

FAM133A

−6.93

4.20E−45

family with sequence similarity 133, member A

ACPP

−7.14

5.48E−32

acid phosphatase, prostate

PTX3

−7.23

1.76E−35

pentraxin 3, long

DCC

−7.24

6.16E−23

deleted in colorectal carcinoma

FARP1

−7.26

1.40E−24

FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte-derived)

BDKRB1

−7.27

0.00E+00

bradykinin receptor B1

TFPI2

−7.56

0.00E+00

tissue factor pathway inhibitor 2

IL1RN

−8.00

5.74E−19

interleukin 1 receptor antagonist

FOXF1

−8.20

0.00E+00

forkhead box F1

DDIT4L

−8.25

2.01E−37

DNA-damage-inducible transcript 4-like

Top 100 microarray hits demonstrating the most significantly up- and downregulated genes in Cav-1 overexpressing U-87MG cells. For a complete list
see Table S2. (n = 3 samples from each group).
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Table 1. Differential gene expression of Cav-1 overexpressing U-87MG cells (continued)
Probe

Fold change

p-value

Description

COL13A1

−8.38

0.00E+00

collagen, type XIII, α 1

VAT1L

−8.62

2.06E−29

vesicle amine transport protein 1 homolog (T. californica)-like

PLAU

−9.17

4.46E−25

plasminogen activator, urokinase

BEX1

−9.73

4.20E−45

brain expressed, X-linked 1

MGC87042

−13.51

2.14E−20

STEAP family protein MGC87042

TFAP2C

−13.77

0.00E+00

transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma)

STC1

−15.24

2.80E−45

stanniocalcin 1

SBSN

−16.74

0.00E+00

suprabasin

MMP3

−19.01

0.00E+00

matrix metallopeptidase 3 (stromelysin 1, progelatinase)

IL1B

−25.20

0.00E+00

interleukin 1, β

MMP1

−37.04

0.00E+00

matrix metallopeptidase 1 (interstitial collagenase)

Top 100 microarray hits demonstrating the most significantly up- and downregulated genes in Cav-1 overexpressing U-87MG cells. For a complete list
see Table S2. (n = 3 samples from each group).
Table 2. Cav-1 regulates cancer-associated gene expression
A. Gene ontology: Biological process
Gene Set

Enrichment Score (ES)

Normalized ES

Nominal p-value

FDR q-value

NEGATIVE_REGULATION_OF_SIGNAL_TRANSDUCTION

0.500

2.023

< 0.001

0.092

REGULATION_OF_TRANSFORMING_GROWTH_FACTOR_BETA_
RECEPTOR_PATHWAY

0.619

1.846

< 0.001

0.071

CASPASE_ACTIVATION

0.566

1.748

< 0.001

0.067

NEGATIVE_REGULATION_OF_MAP_KINASE_ACTIVITY

0.521

1.537

< 0.001

0.160

NEGATIVE_REGULATION_OF_CELL_PROLIFERATION

0.331

1.460

< 0.001

0.190

NEGATIVE_REGULATION_OF_TRANSCRIPTION

0.340

1.367

< 0.001

0.211

APOPTOSIS_GO

0.313

1.338

< 0.001

0.227

POSITIVE_REGULATION_OF_CELL_ADHESION

0.501

1.308

< 0.001

0.243

Gene set

Enrichment score (ES)

Normalized ES

Nominal p-value

FDR q-value

BIOCARTA_AKT_PATHWAY

0.647

1.965

< 0.001

0.137

SA_PROGRAMMED_CELL_DEATH

0.739

1.923

< 0.001

0.142

KEGG_ECM_RECEPTOR_INTERACTION

0.496

1.857

< 0.001

0.158

KEGG_MTOR_SIGNALING_PATHWAY

0.487

1.831

< 0.001

0.125

REACTOME_PI3K_AKT_SIGNALING

0.479

1.682

< 0.001

0.144

REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS

0.423

1.592

< 0.001

0.142

BIOCARTA_ERK_PATHWAY

0.493

1.583

< 0.001

0.151

KEGG_APOPTOSIS

0.360

1.521

< 0.001

0.169

B. Canonical pathways

ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate. q-value for selected gene sets enriched in LV105 Cav-1 cells vs.
control using (A) gene ontology: biological process and (B) canonical pathway molecular signature databases (n = 3 samples from each group). For a
detailed list of genes see Table S1.

Discussion
Although it has been demonstrated that Cav-1 expression in glioma increases variably in accordance with grade, little is currently
known about its biological effects on tumor onset and progression.12-14,17-19 Previous in vitro studies using transient transfection
techniques have shown that loss of Cav-1 in U-87MG cells resulted
in the adoption of a more proliferative and invasive phenotype,

1514

whereas its forced overexpression conferred the opposite effects.15
In line with previous studies, we here show that Cav-1 functions
as a putative tumor suppressor in glioblastoma. Using a novel lentivirus transduction system we created a stable Cav-1 overexpressing cell line based on the U-87MG background.
By subjecting transiently transfected U-87MG cells to a panel
of reverse transcription-PCR primers, Martin et al. identified
genes pertaining to cell invasion, metastasis and cell adhesion as
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Figure 2. Cav-1 mediates major proliferative and cell survival pathways.
Western immunoblot analysis of LV105 control and LV105 Cav-1 U-87MG
cells showing cyclin D1 and cleaved caspase-3 expression as well as
phosphorylation status of ERK1/2, AKT, mTOR and RPS6 pathways, with
respective total protein levels for loading controls. Total caspase-3 and
GAPDH serve as loading controls for cleaved caspase-3 and cyclin D1,
respectively.

those being the most differentially regulated by Cav-1 expression.
Particularly, they showed that the integrin genes ITGA1, ITGA3,
ITGA5, ITGAV, ITGB1 and ITGB5 were significantly downregulated in Cav-1-overexpressing cells, with cells treated with Cav1-specific siRNA demonstrating marked upregulation of these
same genes. Matrix metallopeptidase genes MMP1 and MMP2
as well as transforming growth factor β receptor I (TGFRBI)
were also shown to be significantly modulated by Cav-1.15 A follow-up study using Cav-1-silenced U-87MG cells further clarified a mechanism in which Cav-1 acts as a negative regulator of
integrin signaling by inhibiting the expression of these integrins
themselves as well as sequestering downstream TGFβ/TGFβRI/
SMAD2 and ERK pathways.16 Here, we implemented a similar,
albeit much more expansive, microarray-based approach to study
gene perturbations as a result of Cav-1 overexpression. Using
gene set enrichment analyses, we indeed show similar expression
profiles to those found previously, with gene sets related to integrin interactions, as well as regulation of TGFβ receptor/SMAD
pathways showing significant enrichment. In our study, however,
we detected a multitude of other significantly enriched gene sets
that have not been demonstrated previously in Cav-1-expressing
GBM cells. For instance, U-87MG cells overexpressing Cav-1
demonstrated significant upregulation of genes responsible for
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Figure 3. U-87MG cells stably overexpressing Cav-1 exhibit decreased
tumor growth in vivo. (A) Tumor weight and (B) tumor volume of U87MG xenografts grown in athymic nu/nu male mice after 4 wk (n = 30
per group, ***p < 0.001).

negative regulation of signal transduction, particularly within
ERK, PI3K/AKT and mTOR pathways. Although it has long
been known that Cav-1 serves to negatively regulate the activity
of p42/p44 (ERK1/2) signaling proteins of the MAPK pathway,
our evidence also suggests it has the capability to sequester PI3K
and mTOR activity.20-26 This is notable due to the fact that ERK,
PI3K and mTOR signaling axes are frequently upregulated in
GBM, suggesting that loss of Cav-1 could lead to unchecked activation of these pathways.27-31 Two of the most commonly silenced
genes in GBM are the tumor suppressor proteins PTEN and
TP53, which serve to antagonize the PI3K/AKT/mTOR pathway and regulate cell cycle response to DNA damage and cell
death, respectively.32 Of note is that these two genes were among
the most upregulated in cells overexpressing Cav-1, which would
likely explain the gene signatures corresponding to downregulation of signaling pathways and reduced invasiveness.
A major hallmark of GBM is the ability of tumor cells to
invariably metastasize to distant sites in the CNS despite aggressive treatment. This is often attributed to the excessive release of
matrix metallopeptidases and urokinase plasminogen activator.33
Here we show that the genes MMP1, MMP3 and PLAU (urokinase plasminogen activator) are highly downregulated in our
Cav-1-overexpressing U-87MG cells, which is consistent with
reports that Cav-1 negatively regulates tumor invasiveness.15,34-36
These genes have been shown to be regulated by Erk and TP53,
therefore, their reduction may be secondary to Cav-1 modulation of these pathways.37-40 Of note, we also found that genes
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responsible for sequestering cell cycle progression and
transcription were overexpressed in LV105 Cav-1 cells
(FOXN3, HDAC5, VHL, CDKN1C, among others). Conversely, genes responsible for progression
through cell cycle, such as CCND1 (cyclin D1), were
found to be significantly downregulated in Cav-1overexpressing cells, consistent with previous reports
that Cav-1 transcriptionally represses cyclin D1.8
Perhaps our most notable finding, however, is that a
substantial number of genes involved in the activation of apoptotic and cell death pathways are increased
as a result of Cav-1 overexpression (TP53, MOAP1,
CASP3, CASP9, BCL2L11, BAK1, BID among others). Although the role of Cav-1 in apoptosis is contentious, with reports indicating both pro- and anti-cell
death roles, it may be possible that expression of Cav-1
promotes apoptotic activity in U-87MG cells by inhibiting the BIRC5 gene product, survivin, as is suggested
here and in previous reports.41-45 In support of these
microarray data, we were able to demonstrate, at the
protein level, silencing of ERK, AKT, mTOR, RPS6
and cyclin D1 pathways with corresponding activation
and cleavage of the key apoptosis initiator caspase 3.
Importantly, we here show for the first time that
forced expression of Cav-1 in vivo results in a dramatic reduction of tumor burden in U-87MG xenografts. Although Cosset et al. have demonstrated that
explanted human glioma tissue lacking Cav-1 expression results in increased expression of α5β1 integrin
subunits, we were able to demonstrate a direct inverse
relationship with Cav-1 expression and cell proliferation in an animal model.16 In line with our in vitro
data, these xenograft tumors displayed reduced activity of ERK, RPS6 and mTOR pathways. As these pathways have been previously shown to play major roles in
glioma progression, it is likely that Cav-1 could act as a
critical regulator of tumor growth and protein synthesis in a clinical setting. As examples of this, studies have
shown that exogenous administration of cavtratin, or
a soluble peptide consisting of the Cav-1 scaffolding
Figure 4. Cav-1-overexpressing tumors show reduced signaling activity in vivo.
domain fused to an internalization domain, results in
Immunohistochemical staining of explanted tumors for Cav-1, cyclin D1 and phosphorylated ERK1/2, mTOR and RPS6 (magnification = 60×).
reduced MAPK activity in oligodendroglial cells in
vivo, as well as reduced tumor volumes in a xenograft
model of Lewis lung carcinoma.23,46 A separate study
demonstrated that in vitro administration of full-length Cav-1 associate with P-gp and negatively regulate its activity; therefore,
prevented invasion of three different GBM-derived cell lines overexpression of Cav-1 most likely results in improved access of
using a Boyden-chamber assay.47 In this regard, it may be sug- TMZ to the intracellular compartment of U-87MG cells in our
gested that Cav-1 be explored as a therapeutic agent in GBM.
model.49,50 Interestingly, a separate study showed that treatment
Lastly, we have also demonstrated that expression of Cav-1 with TMZ resulted in upregulation of Cav-1 expression in vivo
confers sensitivity to the most commonly used chemotherapeutic using orthotopic GBM xenograft models.47 In light of our data,
in GBM, temozolomide. This could be due in part to the action this could suggest a positive feedback loop exists in which treatof the permeability glycoprotein (P-gp) transporter, a multidrug ment with TMZ serves to auto-sensitize GBM cells through a
exporter that normally prevents the influx of drugs across the Cav-1 dependent mechanism. This finding implicates Cav-1 as
blood brain barrier. However, cancerous cells can also express a potential biomarker predicting response to chemotherapies for
this protein, rendering treatment of GBM with conventional GBM, as it has been shown for other cancers such as breast, lung
chemotherapeutics less effective.48 Cav-1 has been shown to and oral squamous cell carcinomas.51-53
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Figure 5. Cav-1 confers chemosensitivity in U-87MG cells. Annexin V and
propidium iodide staining of U-87MG cells treated with either DMSO control or 500 μm TMZ reveals percentages of (A) live cells, (B) early apoptotic
cells, (C) late apoptotic cells and (D) dead cells as measured by flow cytometry. Each group is normalized to its own DMSO control (*p < 0.05 and **p
< 0.01 vs. internal DMSO control, †p < 0.01 vs. TMZ treated LV105 control,
n = 3 per group).

Taken together, these studies confirm and expand upon previous work identifying Cav-1 as a putative tumor suppressor in
GBM. We here show that stable overexpression of Cav-1 in a
widely used model of GBM results in silencing of key proliferative and cell survival pathways in vitro as well as in vivo (Fig. 6).
Additionally, we have demonstrated its ability to modulate sensitivity to commonplace chemotherapeutics for GBM. These findings highlight the potential of Cav-1 to serve as a novel biomarker
indicating potential response to therapy and also a candidate
therapy for treatment of GBM.
Materials and Methods
Cell lines and reagents. The human glioblastoma-derived
cell line U-87MG was obtained from American Type Culture
Collection (ATCC) and cultured in Eagle’s modified essential
medium (EMEM, ATCC) supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin (Life Technologies). Cells
were cultured in the presence of 5% CO2 at 37°C. Temozolomide
(TMZ) was obtained from Sigma-Aldrich and dissolved in
DMSO to a concentration of 100 mM. The following antibodies
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were used: mouse anti-Caveolin-1 (2297, BD Bioscience), rabbit anti-Caveolin-1 (N-20, Santa Cruz Biotechnology), mouse
anti-cyclin D1 (DCS-6, Santa Cruz Biotechnology), rabbit
anti-phospho mTOR (Se2448, D9C2, Cell Signaling), rabbit anti-phospho-ERK1/2 (Thr202/Tyr204, Cell Signaling),
rabbit anti-phospho-AKT (Ser473, D9E, Cell Signaling),
rabbit anti-phospho-ribosomal S6 (Ser235/236, 91B2, Cell
Signaling) rabbit anti-ERK1/2 (Cell Signaling), rabbit antiAKT (Cell Signaling), rabbit anti-ribosomal S6 (5G10,
Cell Signaling), rabbit anti-cleaved caspase 3 (Asp175, Cell
Signaling), rabbit anti-caspase 3 (Cell Signaling) and mouse
anti-GAPDH (6C5, Fitzgerald Industries).
Stable lentiviral transduction of U-87MG cells. Plasmids
Ex-Neg-LV105 (empty control vector) and Ex-D0159-LV105
(Cav-1 cDNA vector) were obtained from Genecopoeia and
transfected into the packaging cell line Genecopoeia 293Ta
using the Lenti-Pac HIV Expression Packaging Kit as per
manufacturer’s instructions. Forty-eight h post-transfection,
lentivirus containing supernatants were collected and centrifuged at 500 × g for 10 min to clear cellular debris. U-87MG
cells were cultured in viral supernatants supplemented with
5 μg/ml polybrene (Santa Cruz) for 24 h prior to changing
back into complete medium containing 2.5 μg/ml puromycin
hydrochloride (Santa Cruz) to select for lentiviral-transduced
cells. After 1 wk of selection, cells were allowed to grow in
complete medium without puromycin.
Western immunoblot. Cells at 70% confluence were collected, pelleted at 300 × g, washed twice with Dulbecco’s PBS
(DPBS) and resuspended in RIPA lysis buffer (50 mM Tris,
150 mM NaCl, 0.5% sodium deoxycholate, 1% Triton X-100,
0.1% SDS, pH 7.5) including Complete Protease Inhibitor
Cocktail (Roche Diagnostics) and Halt Phosphatase Inhibitor
Cocktail (Thermo-Scientific). Lysates were sonicated and centrifuged at 10,000 × g for 10 min to clear cellular debris prior
to protein quantification by BCA assay (Thermo-Scientific)
as per manufacturer’s instructions. Proteins were separated by
sodium dodecyl sulfate PAGE (SDS-PAGE; 8–12% acrylamide),
transferred to nitrocellulose membranes (Whatman) and blocked
for 1 h in TBST (10 mM Tris, 150 mM NaCl, 0.05% Tween-20,
pH 8.0) with 5% bovine serum albumin (BSA). Membranes were
incubated with primary antibodies diluted in TBST + 1% BSA
overnight at 4°C followed by incubation in either horseradish
peroxidase (HRP) conjugated anti-mouse (Thermo-Scientific)
or anti-rabbit (BD Biosciences) antibodies. Detection of bound
antibodies was accomplished with the use of Supersignal chemiluminescent substrates (Thermo-Scientific).
Immunofluorescence analysis. U-87MG cells grown on glass
coverslips in 6-well plates were fixed in ice-cold methanol for 20
min, washed with PBS and incubated with anti-Cav-1 primary
antibody (BD Bioscience) in immunofluorescence (IF) buffer (PBS + 5% BSA, 0.5% NP40) for 30 min at 37°C before
incubation with secondary fluorescein isothiocyanate (FITC)conjugated anti-mouse antibody (Jackson Labs) in IF buffer. Cells were counterstained with Hoechst nuclear dye (Life
Technologies) prior to coverslipping and visualization with a
Zeiss LSM 510 confocal microscope (Carl Zeiss Microscopy).
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Figure 6. Schematic representation of the role of Cav-1 in glioblastoma. Gliomas are highly heterogeneous tumors that have been demonstrated to
contain populations of cells with varied levels of Cav-1 expression. In this case, enhanced Cav-1 expression among a tumor cell prevents the activation
of the TGFBRI/SMAD pathway, which, in turn, suppresses expression of integrin subunits at the transcriptional level and their subsequent signaling
activity. Increased Cav-1 expression is also correlated with a decrease in the availability of matrix metallopeptidases, downregulated activity of the
Erk1/2, PI3K/Akt and mTOR signaling pathways as well as the inhibition of the trans-membrane drug exporter p-gp. Together, this may implicate that
tumors with increased Cav-1 levels are less likely to progress through the cell cycle or invade into surrounding tissues and are primed to undergo P53
mediated apoptosis, making these cells more easily targeted by standard chemotherapy regimens.

Gene array. DNA microarray analysis was performed using
the Human Whole Genome OneArray v2 (Phalanx Biotech).
RNA quality and integrity were determined utilizing an Agilent
2100 Bioanalyzer (Agilent Technologies) and absorbance at
A260/A280. Only high quality RNA, having a RIN of > 7.0
and an A260/280 absorbance ratio of > 1.8, was utilized for further experimentation. RNA was synthesized to double-stranded
cDNA and amplified using in vitro transcription that included
amino-allyl UTP, and the aRNA product was subsequently
conjugated with Cy5 NHS ester (GE Healthcare Lifesciences).
Fragmented aRNA was hybridized at 42°C overnight using
the HybBag mixing system with 1× OneArray Hybridization
Buffer (Phalanx Biotech), 0.01 mg/ml sheared salmon sperm
DNA (Promega), at a concentration of 0.025 mg/ml labeled
target. After hybridization, the arrays were washed according to
the OneArray protocol. Raw intensity signals for each microarray were captured using a Molecular Dynamics™ Axon 4100A
scanner, measured using GenePixPro™ Software. Significantly
up or downregulated genes in LV105 Cav-1 cells were identified
as having normalized intensities above background (> 50), a fold
change of ± 1.5 compared with control and p < 0.05.
Gene set enrichment analyses. Pre-processed expression
data was subjected to Gene Set Enrichment Analysis using
C5.BP.V3.0 (gene ontology: biological processes) and C2.CP.
V3.0 (canonical pathways) MSigDB gene sets.54,55 Genes
expression data were ordered based on a Signal2Noise metric
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and compared statistically to existing gene sets at a resolution of
1,000 permutations. Statistical significance of gene set enrichment was assumed at nominal p < 0.05, with a false discovery
rate (FDR) q < 0.25.
Tumor xenografts. All animal studies were conducted in
accordance with the guidelines set forth by the National Institutes
of Health and the Thomas Jefferson University Institutional
Animal Care and Use Committee (IACUC). Briefly, U-87MG
cells were washed with DPBS, trypsinized, counted and resuspended in a volume of complete medium yielding 1 × 106
cells/50 μl, which was subsequently injected subcutaneously into
the flanks of 6–8-wk-old male athymic nu/nu mice (NCI). After
4 wk, mice were sacrificed and tumors were excised, weighed and
measured prior to further processing.
Immunohistochemistry. Explanted xenograft tumors were
fixed in 10% phosphate buffered formalin solution for 24 h prior
to dehydration in 70% ethanol, paraffin embedding and sectioning onto slides. Following xylene deparaffinizaiton and rehydration, slides were subjected to 10 min of heat antigen retrieval in
10 mM sodium citrate buffer pH 6.0 and endogenous peroxide
quenching in 3% hydrogen peroxide for 20 min. Tissues were
blocked in 10% normal goat serum (NGS, Vector Labs) for 1 h
at room temperature and incubated overnight with primary antibody in 10% NGS at 4°C. Slides were then washed in PBS and
blocked with Biotin-Blocking System (Dako) before incubating
with the appropriate secondary antibody in PBS and developing
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with 3,3-diaminobenzidine (DAB) substrate (Dako). Slides were
counterstained with hematoxylin (Sigma), dehydrated and coverslipped prior to imaging with an Olympus BX51 light microscope
equipped with a Micropublisher 5.0 CCD camera (QImaging).
Flow cytometry. U-87MG cells (50,000/well) were plated
in 12-well tissue culture dishes and allowed to attach overnight
prior to changing their medium into complete EMEM containing either 500 μM TMZ or DMSO control and culturing them
for an additional 72 h. Cells were then trypsinized, centrifuged
at 300 × g for 5 min and resuspended in binding buffer with
APC-conjugated anti-Annexin V antibody (BD Biosciences) and
0.33 μg/ml Propidium Iodide (PI, KPL). All samples were run
on a BD FACSCalibur flow cytometer (BD Biosciences). Cells
were quantified according to staining as follows: viable (Annexin
V-negative, PI-negative), early apoptotic (Annexin V-positive,
PI-negative), late apoptotic (Annexin V-positive, PI-positive) and
dead (Annexin V-negative, PI-positive).
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